Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Theresa Kehoe

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Osteoporosis Reports|July 11, 2006
Bone quality: a perspective from the Food and Drug AdministrationTheresa Kehoe
British Journal of Clinical Pharmacology|October 19, 2018
Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspectiveTheresa Kehoe, Eberhard Blind, Heidi Janssen
The New England Journal of Medicine|May 11, 2012
Bisphosphonates for osteoporosis--where do we go from here?Marcea Whitaker, Jia Guo, Theresa Kehoe, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2004
Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemiaTodd T Brown, Mary D Ruppe, Rory Kassner, et al.
Clinical Pharmacology and Therapeutics|April 27, 2025
US Food and Drug Administration's Advancing Real-World Evidence Program: Initial ExperienceKimberly A Smith, Yin Huang, Theresa Kehoe, et al.
Journal of Clinical Pharmacology|February 28, 2018
Regulatory Perspectives in Pharmacometric Models of OsteoporosisKumpal Madrasi, Fang Li, Myong-Jin Kim, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Osteoporosis Reports|July 11, 2006
Bone quality: a perspective from the Food and Drug AdministrationTheresa Kehoe
British Journal of Clinical Pharmacology|October 19, 2018
Regulatory aspects of the development of drugs for metabolic bone diseases - FDA and EMA perspectiveTheresa Kehoe, Eberhard Blind, Heidi Janssen
The New England Journal of Medicine|May 11, 2012
Bisphosphonates for osteoporosis--where do we go from here?Marcea Whitaker, Jia Guo, Theresa Kehoe, et al.
The Journal of Clinical Endocrinology and Metabolism|March 6, 2004
Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemiaTodd T Brown, Mary D Ruppe, Rory Kassner, et al.
Clinical Pharmacology and Therapeutics|April 27, 2025
US Food and Drug Administration's Advancing Real-World Evidence Program: Initial ExperienceKimberly A Smith, Yin Huang, Theresa Kehoe, et al.
Journal of Clinical Pharmacology|February 28, 2018
Regulatory Perspectives in Pharmacometric Models of OsteoporosisKumpal Madrasi, Fang Li, Myong-Jin Kim, et al.
Pageof 1